A Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease
A Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease
Recruiting · NCT06609889 · Registry updated 2025-12-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Epilepsies, Myoclonic, Epilepsy, Generalized, Epileptic Syndromes, Lafora disease, brain disorder, central nervous system disorder, epilepsy, hereditary disease, inherited neurodegenerative disorder, nervous system disorder, neurodegenerative disease, progressive myoclonus epilepsy | Recruiting | Phase 1 / Phase 2 | 2025-12-18 | NCT06609889 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Berge Minassian | 1 |
| Elpida Therapeutics SPC | 5 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Childrens Health | Dallas | United States | 1 |